Effect and Mechanism of Dopamine on Ulcerative Colitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-02-16

Study Completion Date

2022-09-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Increased evidence suggests that dopamine acts as an important regulator of immune function. A substantial amount of dopamine exists in the gastrointestinal tract, especially in colonic lumen. Decreased dopamine level has been reported in the colonic mucosa of ulcerative colitis patients. Therefore, the investigators suppose that colonic dopamine could involve in the ulcerative colitis and play an important role. This study aims to explore the role of dopamine in ulcerative colitis and underlying mechanism, which will provide a rationale for diagnosis and treatment of the ulcerative colitis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Observation of the Effect of Vitamin D Supplementation on Chronic Course of Patients With Ulcerative Colitis Based on Vitamin D Receptor Fok I Gene Polymorphism

NCT04309058

Ulcerative Colitis Vitamin D Deficiency Vitamin D Supplement

UNKNOWN EARLY_PHASE1

Vitamin D and Disease Activity in Ulcerative Colitis

NCT02717897

Ulcerative Colitis

COMPLETED

Preliminary Clinical Study of NMN Intervention in Mild Ulcerative Colitis

NCT06214078

Ulcerative Colitis Chronic Mild

RECRUITING NA

Vitamin D Treatment in Ulcerative Colitis

NCT01640496

Ulcerative Colitis Inflammatory Bowel Disease

WITHDRAWN NA

In Vivo Molecular Imaging Predicts Therapeutic Response in Ulcerative Colitis

NCT02852850

Ulcerative Colitis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a case-control clinical study. 30 patients with non-ulcerative colitis examined by endoscopy were selected as the control group. According to the inclusion and exclusion criteria, 30 patients with ulcerative colitis were determined. The baseline data of patients were recorded objectively: name, sex, age, vital signs, body weight and stool condition (frequency, character, etc.). Some laboratory examination results (blood routine, fecal routine and fecal culture, liver function, blood coagulation function, electrolyte, etc.), ulcerative colitis lesion range, ulcerative colitis classification and related history (common disease, treatment history and life history). Colonic mucosal tissue samples of patients with ulcerative colitis and control group were obtained by colonoscopic biopsy. The degree of inflammation was evaluated by related inflammatory factors via ELISA. The changes of dopamine system was detected by HPLC-ECD, Western Blot and immunohistochemistry. This study aims to provide new diagnostic and therapeutic basis, select appropriate drug delivery through clarify the effect and mechanism of local dopamine on colitis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dopamine Dysregulation Syndrome Ulcerative Colitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ulcerative colitis group

Patients with ulcerative colitis as observation group

Patients diagnosed with ulcerative colitis

Intervention Type OTHER

Patients with ulcerative colitis diagnosed by endoscopy and histopathology

Non-ulcerative colitis group

Non-ulcerative colitis as control group

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Patients diagnosed with ulcerative colitis

Patients with ulcerative colitis diagnosed by endoscopy and histopathology

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with or without ulcerative colitis diagnosed by endoscopy and histopathology
2. Negative bacterial culture in stool
3. Written informed consent

Exclusion Criteria

1. Patients with cardiovascular and cerebrovascular diseases, or patients with severe impairment of liver, kidney and hematopoietic system
2. Mental patients
3. Hemorrhagic diseases
4. Platelet count \< 50 × 10 \^ 9 / L
5. Allergic constitution
6. unable to tolerate or cooperate with endoscopy
7. Patients with serious complications, such as intestinal obstruction, intestinal perforation, toxic colonic dilatation, colorectal cancer, etc.
8. Pregnant or lactating women

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes